Biyo Pharma key facts
- Developer of innovative drug designed for nervous system disease.
- It has raised $14.3M; the latest was Early Stage VC ($14.3M) in Jan 2026.
- Notable investors include Lapam Capital, Tailong VC, Hangzhou Capital, Shanghai Healthcare Capital, Jingjie Investment — 8 tracked in total.
- Status: Privately Held (backing).
- ·Watch Biyo Pharma: the Monday email on marks, rounds and moves
Biyo Pharma funding rounds
No funding rounds for Biyo Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Biyo Pharma investors
8 investors are on record for Biyo Pharma, including Lapam Capital, Tailong VC, Hangzhou Capital and Shanghai Healthcare Capital.
About Biyo Pharma
Developer of innovative drug designed for nervous system disease. The company focuses on the research and development of nervous system disease related drugs for episodic migraine and chronic migraine symptoms, providing patients with better medical treatment.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2021
- Employees
- 5
- Website
- biyopharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Biyo Pharma doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.